Board & Management team

Mr Mark Diamond is a senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than thirty years within the pharmaceutical and biotechnology industries. In May 2023, Mark retired from ASX listed Antisense Therapeutics Limited as Managing Director and CEO, a position he had held since 2001, making him at the time of his retirement the longest serving CEO of a publicly traded Healthcare Company on the ASX. At Antisense, Mark was responsible for capital market engagement, pipeline development, product out-licensing and clinical trial conduct among other significant accomplishments. In 2022, Mark was the recipient of The Biotech Daily CEO of the Year award. Prior to his time at Antisense, Mark served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations.

Mark holds a Bachelor of Science degree from Monash University and an MBA from Macquarie University.

Nina has over thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina was formerly the Commercial Director for Acrux Limited (ASX: ACR), an Australian drug pharmaceutical company that has successfully developed and commercialised multiple products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK. Nina is also the Non-Executive Chairperson for SYNthesis BioVentures and a Non-Executive Director for Linear Clinical Research Limited. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an Executive MBA from RMIT.

Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. Hugh has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has a track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products.

Hugh is currently CEO of Kinoxis Therapeutics, a private company developing novel therapeutics for substance use disorders and other neurological conditions. Prior to Kinoxis, Hugh was CEO of venture-backed private company Hatchtech Pty Ltd, where he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that licensed the testosterone product Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.

Clinton Snow has over 20 years experience as a technology leader with a focus in engineering management, project delivery, risk management, and assurance. Clinton is currently a non-executive director for Icetana Ltd (ASX:ICE) and provides advisory services to a family office with multiple Australian biotech investments.

Clinton holds a Bachelor of Chemical Engineering (honours) and Bachelor of Commerce degree from The University of Melbourne.

Dr. Poli is an accomplished R&D executive with 25+ years progressive experience in private and publicly listed pharmaceutical companies. She has broad expertise which encompasses multiple therapeutic areas, in large indications as well as rare orphan indications and has an established track record of leading projects through key scientific, regulatory, and partnership milestones.  

Sonia is currently Chief Sceintific Officer at Sibylla Biotech, a preclinical stage company focused on developing small molecule degraders with a novel Mechanism of Action.She previously held various management positions AC Immune, Minoryx, Addex therapeutics, and Hoffmann la Roche.  

Dr. Poli holds a PhD in Industrial Chemistry from the University of Milan and is co-author of several patents and more than 50 scientific publications.

Hamish has experience in providing financial advice and CFO services to businesses ranging from small start-ups to large established businesses with turnover of over $50 million. He brings expertise in areas including financial/management reporting, Company Secretarial, cash flow management, taxation including (R&D Tax Incentive), Company Establishments, company valuations, budgeting and forecasting. Hamish is also a member of the senior management team at Bio101, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector. Hamish holds a Bachelor of Commerce from the University of Melbourne, a Diploma in Financial Planning from Kaplan Professional, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

David is an internationally experienced pharmaceutical executive and physician, with over 35 years of international experience in drug development and commercialisation. David has a strong background product development, as well as a successful history of securing multiple INDs/NDAs (or equivalent) with both the FDA and EMA. He has led teams that successfully obtained major market product approvals for Renagel (chronic kidney disease, EU, including post-approval support) Moraxen (cancer pain, UK), Busulfex (haematologic oncology; US Paediatrics and EU Adult indications), Xyrem (narcolepsy; US).

David has extensive experience in product development and commercialization, from Planning, Financing, Pre-clinical, Clinical Development, Regulatory Approval, Product Launch, Pharmacovigilance, and Medical Affairs. He has designed and executed multiple GCP Phase 1-3 studies across the US, EU, and Asia for both orphan and major market products.

David has a proven track record of creating value across private and ASX listed large and small-cap environments. David was the former CMO of Race Oncology,  and is also a Non-Executive Director at AdAlta Limited and EpiAxis Therapeutics Pty Ltd. David holds Bachelor of Medicine/Bachelor of Surgery and Bachelor of Pharmacy degrees from University of Sydney.

Robert is an experienced pharmaceutical executive having lead multidisciplinary research and development teams for over 11 years. Prior to joining the Dimerix team, Robert was a Senior Development Manager at Medicines Development for Global Health, a non-profit organisation focused on efficiently developing drugs for orphan and neglected indications. In this role, he supported biotechnology and academic groups in project management roles spanning research, manufacturing, nonclinical, clinical and regulatory fields in pain, immunology, infectious diseases, and oncology. Robert has previously held roles as a Business Analyst at the Monash Vision Group, Communications Advisor at the Australian Society of Plant Scientists, and Sessional Lecturer at Monash University. Robert holds a BS in Genetics (Honours), PhD in molecular cell biology and immunology, an executive MBA and a graduate certificate in science commercialisation from Monash University, Australia.

Bronwyn Pollock is an experienced biotech and pharmaceutical professional with over 20 years in the industry. Prior to leading the Product Development work at Dimerix, Bronwyn was Director of Product Development at Prota Therapeutics. She has also held Senior Management positions in pharmaceutical companies including Neuren Pharmaceuticals Ltd, Hospira Australia (now Pfizer), Acrux Ltd and CSL. Her CMC (Chemistry, Manufacturing and Controls) experience comes from working in R&D, quality and program management, and she has been involved in leading teams in the development and submission of numerous dossiers to EMA, US FDA, Asia and Sth America, technology transfers and launch.